Cohance Lifesciences files SEBI disclosure on share acquisition by CSC Global Capital Markets

What Cohance Lifesciences announced

Cohance Lifesciences Ltd (BSE: 543064) filed a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 19 June 2026. The filing informs the market that CSC Global Capital Markets (Singapore) Pte Ltd has acquired a substantial shareholding in Cohance, thereby invoking the mandatory reporting requirement.

The announcement itself contains no quantitative details such as the percentage of shares acquired or the consideration paid. It merely records the existence of a qualifying acquisition and identifies the acquiring entity.

Regulation 29(1) – when a filing is required

Regulation 29(1) mandates that any person or entity acquiring 5 % or more of the voting share capital of a listed company must promptly disclose the acquisition to the stock exchange. The purpose is to ensure transparency for shareholders and the market about changes in control or significant influence.

Key points of the regulation include:

• Immediate filing within two trading days of the acquisition.
• Disclosure of the acquirer's identity, the number of shares acquired, and the percentage of total share capital.
• Subsequent filings if the shareholding crosses additional thresholds (e.g., 10 %, 15 %).

In this case, Cohance has complied by submitting the required form, but the public document does not reveal the exact numbers.

About the acquiring entity – CSC Global Capital Markets (Singapore) Pte Ltd

CSC Global Capital Markets (Singapore) Pte Ltd is a Singapore‑registered investment vehicle. The filing does not provide background on its investment strategy, prior holdings, or relationship with Cohance. Its appearance as a substantial shareholder suggests a strategic interest in the biotech/pharma sector, but any further interpretation would be speculative.

Key facts at a glance

Why this matters for investors

The filing signals that a foreign investor has taken a material stake in Cohance, which could lead to changes in governance, strategic direction, or future capital actions. While the exact size of the holding is unknown, the requirement to file under Reg 29(1) confirms that the stake meets or exceeds the 5 % threshold. Investors should watch for follow‑up disclosures that will detail the percentage held, any voting agreements, or plans for further investment. Such information can affect voting dynamics and may influence board composition or corporate strategy.

Conclusion

Cohance Lifesciences has complied with SEBI’s takeover disclosure rules by filing a Reg 29(1) notice on 19 June 2026, acknowledging that CSC Global Capital Markets (Singapore) Pte Ltd has acquired a substantial shareholding. The filing does not reveal the exact stake or financial terms, and further disclosures are expected to provide those details. Investors should stay alert for subsequent filings that will clarify the extent of the acquisition and any related corporate actions.